pharmaceutical investing Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05
Prismo Metals Assay Results at Silver King Show Highs of 1.73% copper, 30 ppm molybdenum, 1,362 g/t silver, 4.1% lead, and 1.3 g/t gold
